THREE International Expands Product Listing
In a significant development for the MLM health supplement sector, THREE International has announced that its metabolic health supplement, GLP THREE™, is now included in the prestigious Prescriber’s Digital Reference (PDR). This addition brings the total number of THREE products listed in the PDR to seven, underscoring the company's commitment to quality and transparency.
Why This Matters
The PDR is a vital resource for healthcare professionals, offering standardized information on product ingredients, safety, and usage. For THREE International, being listed in this trusted clinical platform enhances credibility among medical professionals and potential customers. This validation indicates that their formulations are backed by scientific evidence, which is crucial in the competitive wellness market.
Details on GLP THREE™
GLP THREE™ features a proprietary blend known as Metabolic Boost Complex-267 (MBC-267™), containing 320 mg of their specialized complex. The formulation includes bioactive peptides derived from salmon protein, mushroom glycolipids, and botanical extracts such as Panax ginseng and saffron. Research cited in the PDR suggests that GLP THREE™ may help support the health of the GLP-1 metabolic pathway in the body, contributing to improved metabolic health.
Innovative Absorption Technology
THREE International highlights that GLP THREE™ utilizes proprietary cellular absorption technology. This approach is designed to optimize nutrient uptake, ensuring that consumers receive the benefits of its ingredients effectively. This focus on scientific advancement is significant in a market where efficacy is often questioned.
“Having GLP THREE included in the Prescriber’s Digital Reference is an important milestone and strong validation of the science behind our formulations.” — Dr. Dan Gubler, Chief Scientific Officer, THREE International
Commitment to Quality and Transparency
In addition to the PDR listing, THREE International emphasizes that all its products undergo rigorous third-party laboratory testing. This process verifies potency, purity, and safety, and screens for heavy metals and contaminants. Such transparency builds trust with both distributors and consumers, who seek assurance that the products they sell or consume are safe and effective.
What This Means for Distributors and Consumers
For distributors, the inclusion of GLP THREE™ in the PDR could serve as a powerful selling point. It not only enhances the reputation of the product but also provides distributors with credible backing when discussing the supplement with potential customers. For consumers, this means they have access to verified products that are backed by scientific research, potentially leading to better health outcomes.
Looking Ahead
As THREE International continues to expand its product range and enhance its visibility in the healthcare community, stakeholders should keep an eye on further developments. Upcoming product launches or additional PDR listings could provide even greater validation of their offerings and expand their market presence.
For more information on THREE International and its full range of products, visit their official website.
Disclaimer: Statements related to GLP THREE have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
